Supplemental Material

Table S1. List of HIV Env-specific antigens used in BAMA antigen panel against maternal and infant plasma samples.

	Antigen	Sequence/description
Env glycoproteins	4403 BMC5 gp120 A244 gp120 gDneg/293F 1086D7 gp120K160N	- Clade C postnatal T/F Env glycoprotein gp120 - RV144 vaccine strain Env glycoprotein gp120 - Clade C T/F Env glycoprotein gp120
	ConC_gp120_WT Con6gp120/B	- Consensus of subtype C Env sequences available in 2001 in the Los Alamos HIV sequence database - Artificial multiclade consensus Env gp120
Scaffold Env constructs	gp70_C.1086CV1/V2 gp70B.caseA V1V2/293F gp70_B.caseA2_V1V2/169K gp70MNV3	- Scaffold V1V2 construct from the T/F C. 1086 strain - Scaffold clade B V1V2 construct (RV144 immune correlate of risk) - Scaffold clade B V1V2 construct with lysine mutation at position 169 (RV144 immune correlate of risk) - Scaffold V3 construct from the MN strain
Peptides	Bio-V2.1086C (clade C V2 peptide) Bio-V2.B (clade B V2 peptide)	KKKTELKDKKHKVHALFYKLDVVP KKKTSIRDKVQKEYALFYKLDVVP
	Bio-V3.C (clade C V3 peptide) Bio-V3.B (clade B V3 peptide)	KKKNNTRKSIRIGPGQTFYATGDIIGDIRQAHC KKKNNTRKSIHIGPGRAFYATGDIIGDIRQAHC (immune correlate of perinatal transmission risk in clade B WITS cohort)
	Clade C MPER	KKKNEQELLELDKWASLWNWFNITNWLW



301 325

Bio-V3.C Peptide: N N T R K S I R I G P G Q T F Y A T G D I I G

Figure S1. Amino acid residue frequency within the V3 loop from 697 HIV Env sequences isolated from clade C virus-infected patients, compared against the Bio-V3.C peptide used in binding assays. Amino acid residues 301 through 325 are depicted, as labeled by the HXB2 numbering scheme.